Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $12.
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $12.